<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704713</url>
  </required_header>
  <id_info>
    <org_study_id>CUV032</org_study_id>
    <nct_id>NCT04704713</nct_id>
  </id_info>
  <brief_title>Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)</brief_title>
  <official_title>A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinuvel Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinuvel Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      This study was to evaluate the safety and efficacy of afamelanotide in patients suffering&#xD;
      from polymorphic light eruption (PLE).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2010</start_date>
  <primary_completion_date type="Actual">December 9, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale</measure>
    <time_frame>From Day 0 to Day 120</time_frame>
    <description>PLE related pruritus was recorded in paper patient diaries commencing using an 11-point Likert scale from 0 (no pruritus) to 10 (most severe pruritus).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency (Number) of Documented PLE Episodes Recorded in Paper Patient Diaries</measure>
    <time_frame>From Day 0 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PLE Episodes Recorded in Paper Patient Diaries</measure>
    <time_frame>From Day 0 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Using the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>At Day 0, Day 60 and Day 120</time_frame>
    <description>The DLQI questionnaire consists of 10 questions, each answered on a categorical scale. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Polymorphic Light Eruption</condition>
  <arm_group>
    <arm_group_label>Afamelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afamelanotide</intervention_name>
    <arm_group_label>Afamelanotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged greater than 18 years&#xD;
&#xD;
          -  Male or female patients with a documented history of PLE diagnosed or confirmed by a&#xD;
             photodermatologist or photobiologist, with a history of PLE related pruritus symptoms.&#xD;
&#xD;
          -  Recurrent PLE episodes that occur at least once a year (as evidenced by PLE related&#xD;
             pruritus symptoms) developing in their own country (to exclude patients affected only&#xD;
             when traveling to sunnier climates)&#xD;
&#xD;
          -  Written informed consent prior to the performance of any study-specific procedure&#xD;
&#xD;
          -  Are willing and able to comply with the conditions specified in the protocol and study&#xD;
             procedures in the opinion of the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently requiring treatment with systemic immunosuppressive agents&#xD;
&#xD;
          -  Documented history of other photosensitivity conditions which may be confused with PLE&#xD;
             or interfere with the assessment of PLE episodes&#xD;
&#xD;
          -  Solarium use in the three months prior to study involvement and throughout the&#xD;
             duration of the study&#xD;
&#xD;
          -  Use of immunosuppressive medications, drugs that cause hyperpigmentation or any other&#xD;
             treatment that in the opinion of the Investigator may interfere with this study&#xD;
&#xD;
          -  Documented presence (&gt; 1 in 320) of Anti-Nuclear Antibody (ANA) and/or positive&#xD;
             Extractable Nuclear Antibody (ENA); historical results from the 3 years prior to&#xD;
             randomisation are acceptable if available&#xD;
&#xD;
          -  In the opinion of the Investigator, any evidence of clinically significant organ&#xD;
             dysfunction, or any clinically significant deviation from normal in clinical or&#xD;
             laboratory parameters&#xD;
&#xD;
          -  History of drug or alcohol abuse (in the last 1 year)&#xD;
&#xD;
          -  Female who is pregnant (confirmed by positive serum beta-Human chorionic gonadotropin&#xD;
             (Î²-HCG) pregnancy test prior to baseline) or lactating&#xD;
&#xD;
          -  Female of child-bearing potential (pre-menopausal, not surgically sterile) that is not&#xD;
             using or is not willing to use adequate contraceptive measures (e.g. oral&#xD;
             contraceptives, condoms, diaphragm plus spermicide, intrauterine device)&#xD;
&#xD;
          -  Sexually active men with partners of child bearing potential not willing to use&#xD;
             barrier contraception during the trial and for a period of three months thereafter&#xD;
&#xD;
          -  Participation in a clinical trial with another Investigational Medicinal Product (IMP)&#xD;
             within 30 days prior to the Screening visit or during the study&#xD;
&#xD;
          -  Hypersensitivity to afamelanotide or any of its components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>February 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2021</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exanthema</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afamelanotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Afamelanotide</title>
          <description>Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Afamelanotide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Afamelanotide</title>
          <description>Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Afamelanotide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale</title>
        <description>PLE related pruritus was recorded in paper patient diaries commencing using an 11-point Likert scale from 0 (no pruritus) to 10 (most severe pruritus).</description>
        <time_frame>From Day 0 to Day 120</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Afamelanotide</title>
            <description>Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Afamelanotide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale</title>
          <description>PLE related pruritus was recorded in paper patient diaries commencing using an 11-point Likert scale from 0 (no pruritus) to 10 (most severe pruritus).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.0" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.47" lower_limit="0.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency (Number) of Documented PLE Episodes Recorded in Paper Patient Diaries</title>
        <time_frame>From Day 0 to Day 120</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of PLE Episodes Recorded in Paper Patient Diaries</title>
        <time_frame>From Day 0 to Day 120</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Using the Dermatology Life Quality Index (DLQI)</title>
        <description>The DLQI questionnaire consists of 10 questions, each answered on a categorical scale. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
        <time_frame>At Day 0, Day 60 and Day 120</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Afamelanotide</title>
          <description>Afamelanotide implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Afamelanotide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo implants were administered on Days 0 and 60. Patients returned to the clinic on Day 120 for the final visit.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device expulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Manager</name_or_title>
      <organization>CLINUVEL PHARMACEUTICALS LIMITED</organization>
      <email>mail@clinuvel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

